BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15756286)

  • 1. Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation.
    Jenke A; Freiberg-Richter J; Johne C; Knoth H; Schleyer E; Ehninger G; Bornhäuser M
    Bone Marrow Transplant; 2005 Mar; 35(6):627-8. PubMed ID: 15756286
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
    Lee KH; Lee JH; Lee JH; Kim WK; Chi HS; Lee JS
    Haematologica; 2001 Sep; 86(9):999-1001. PubMed ID: 11532635
    [No Abstract]   [Full Text] [Related]  

  • 3. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
    Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
    Bonin M; Pursche S; Bergeman T; Leopold T; Illmer T; Ehninger G; Schleyer E; Bornhauser M
    Bone Marrow Transplant; 2007 Feb; 39(4):201-6. PubMed ID: 17211431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
    Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.
    Russell JA; Kangarloo SB; Williamson T; Chaudhry MA; Savoie ML; Turner AR; Larratt L; Storek J; Bahlis NJ; Shafey M; Brown CB; Yang M; Geddes M; Zacarias N; Yue P; Duggan P; Stewart DA; Daly A
    Biol Blood Marrow Transplant; 2013 Sep; 19(9):1381-6. PubMed ID: 23871781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation.
    de Castro FA; Lanchote VL; Voltarelli JC; Colturato VA; Simões BP
    J Clin Pharmacol; 2013 Nov; 53(11):1205-11. PubMed ID: 23955479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
    Perkins JB; Kim J; Anasetti C; Fernandez HF; Perez LE; Ayala E; Kharfan-Dabaja MA; Tomblyn MR; Sullivan DM; Pidala JA; Field TL
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1099-107. PubMed ID: 22198540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
    Almog S; Kurnik D; Shimoni A; Loebstein R; Hassoun E; Gopher A; Halkin H; Nagler A
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):117-23. PubMed ID: 20601034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
    Takamatsu Y; Ogata K; Yamauchi K; Hara S; Kamimura T; Hayashi S; Suzumiya J; Tamura K
    Jpn J Clin Oncol; 2005 Jul; 35(7):400-3. PubMed ID: 15976066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine.
    de Castro FA; Simões BP; Godoy AL; Bertagnoli Trigo FM; Coelho EB; Lanchote VL
    J Clin Pharmacol; 2016 Dec; 56(12):1555-1562. PubMed ID: 27130252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution.
    Nishihori T; Perkins J; Kim J; Field T; Pidala J; Roman-Diaz J; Komrokji RS; Fernandez HF; Anasetti C; Kharfan-Dabaja MA
    Am J Hematol; 2010 Nov; 85(11):904-7. PubMed ID: 20890908
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
    Madden T; de Lima M; Thapar N; Nguyen J; Roberson S; Couriel D; Pierre B; Shpall EJ; Jones RB; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):56-64. PubMed ID: 17222753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
    Kikuchi T; Mori T; Ohwada C; Onoda M; Shimizu H; Yokoyama H; Onizuka M; Koda Y; Kato J; Takeda Y; Hino Y; Mishina T; Sakaida E; Shono K; Nagao Y; Yokota A; Matsumoto K; Morita K; Okamoto S;
    Int J Hematol; 2021 Jan; 113(1):128-133. PubMed ID: 32886279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis.
    Chen Y; Xu LP; Zhang XH; Chen H; Wang FR; Liu KY; Qin J; Yang YL; Huang XJ
    Bone Marrow Transplant; 2018 Jun; 53(6):770-773. PubMed ID: 29725109
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.